Cover Image
市場調查報告書

陣發性夜間血尿症:開發中產品分析

Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 269903
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
陣發性夜間血尿症:開發中產品分析 Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 91 Pages
簡介

陣發性夜間血尿症(血紅素尿症)(PNH)是罕見疾病,病患紅血球較一般更早被破壞。常見有腹痛、腰痛、尿液暗沈、容易出現瘀傷/出血、頭痛、呼吸困難等症狀。致病因素有年齡,肥胖,荷爾蒙療法。治療方法則包含了手術,化療,放射線治療等。

本報告提供陣發性夜間血尿症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

陣發性夜間血尿症概要

治療藥的開發

  • 開發中產品:概要

開發中的治療藥:各企業

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Achillion Pharmaceuticals, Inc.
  • Akari Therapeutics, Plc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amyndas Pharmaceuticals LLC
  • Apellis Pharmaceuticals Inc
  • Epirus Biopharmaceuticals, Inc.
  • Novartis AG
  • Omeros Corporation
  • Ra Pharmaceuticals, Inc.
  • Regenesance BV
  • The International Biotechnology Center (IBC) Generium

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9727IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017, provides an overview of the Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline landscape.

Paroxysmal nocturnal hemoglobinuria is a rare disease in which red blood cells break down earlier than normal. Symptoms include abdominal pain, back pain, dark urine, easy bruising or bleeding, headache and shortness of breath. The predisposing factors include age, obesity and hormone therapy. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 3, 12 and 1 respectively.

Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders).
  • The pipeline guide reviews pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Paroxysmal Nocturnal Hemoglobinuria (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Paroxysmal Nocturnal Hemoglobinuria - Overview
    • Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Paroxysmal Nocturnal Hemoglobinuria - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Paroxysmal Nocturnal Hemoglobinuria - Companies Involved in Therapeutics Development
    • Achillion Pharmaceuticals Inc
    • Akari Therapeutics Plc
    • Alexion Pharmaceuticals Inc
    • Alnylam Pharmaceuticals Inc
    • Amgen Inc
    • Apellis Pharmaceuticals Inc
    • F. Hoffmann-La Roche Ltd
    • ISU ABXIS Co Ltd
    • Novartis AG
    • NovelMed Therapeutics Inc
    • Omeros Corp
    • Ra Pharmaceuticals Inc
    • Regeneron Pharmaceuticals Inc
    • Regenesance BV
  • Paroxysmal Nocturnal Hemoglobinuria - Drug Profiles
    • ACH-4471 - Drug Profile
    • ACH-5228 - Drug Profile
    • ALN-CC5 - Drug Profile
    • AMY-101 - Drug Profile
    • APL-2 - Drug Profile
    • APL-9 - Drug Profile
    • Coversin - Drug Profile
    • eculizumab biosimilar - Drug Profile
    • eculizumab biosimilar - Drug Profile
    • Gene Therapy for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome - Drug Profile
    • GNR-045 - Drug Profile
    • Monoclonal Antibody for Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    • NM-9405 - Drug Profile
    • OMS-721 - Drug Profile
    • OMS-906 - Drug Profile
    • RA-101348 - Drug Profile
    • RA-101495 - Drug Profile
    • ravulizumab - Drug Profile
    • Regenemab - Drug Profile
    • REGN-3918 - Drug Profile
    • RG-6107 - Drug Profile
    • Small Molecule to Inhibit Factor D for C3 glomerulopathy and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    • Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile
    • tesidolumab - Drug Profile
  • Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects
  • Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products
  • Paroxysmal Nocturnal Hemoglobinuria - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Achillion Pharmaceuticals Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Akari Therapeutics Plc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alexion Pharmaceuticals Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Amgen Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Apellis Pharmaceuticals Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by ISU ABXIS Co Ltd, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Novartis AG, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by NovelMed Therapeutics Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Omeros Corp, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Ra Pharmaceuticals Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Pipeline by Regenesance BV, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Dormant Projects, H2 2017
  • Paroxysmal Nocturnal Hemoglobinuria - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Paroxysmal Nocturnal Hemoglobinuria, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top